OOIR: Observatory of International Research

Papers

(The TQCC of Melanoma Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety	18
Development and validation of prognostic nomogram in pediatric melanoma: a population-based study	17
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors	16
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines	16
Causal relationship between sex hormones and cutaneous melanoma: a two-sample Mendelian randomized study	15
Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma	14
Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma	12
Ponatinib-induced eruptive nevi and melanocytic proliferation	11
Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis	10
Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice	10
Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study	10
Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma	10
Eruptive melanocytic nevi in a patient with amelanotic melanoma: a paraneoplastic phenomenon?	10
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	10
Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients	10
Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis	10
Management of metastatic bone disease of melanoma	9
Regorafenib in patients with pretreated advanced melanoma: a single-center case series	9
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	9
Simultaneous melanomas in the setting of multiple primary melanomas	8
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma	8
Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study	8
Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity	8
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?	7
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting	7

The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis	7
Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging	7
Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study	7
The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio	7
The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy	7
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases	7
High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma	7
A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade	6
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread	6
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1	6
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	6
The potential of using artificial intelligence to improve skin cancer diagnoses in Hawai‘i’s multiethnic population	6
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	6
Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens	6
Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells	6
The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic	6
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	6
ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells	6
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma	6
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	6
Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study	5
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma	5
Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlle	5
The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxygl	5
MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance	5
Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature	5
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	5
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	5
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	5
Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis	5
Molecular profiling of primary uveal melanoma: results of a Polish cohort	5
Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib	4
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report	4
Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10/STAT3 axis in melanoma tumor microenvironment	4
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era	4
The effect of COVID-19 on early melanoma detection	4
Metabolomic characterisation of progression and spontaneous regression of melanoma in the melanoma-bearing Libechov minipig model	4
The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma	4
Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort	4
Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response	4
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy	4
Seborrheic keratosis-like melanoma: a diagnostic challenge	4
Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma	4
Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies	4
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series	4
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection	3
Melanomas and mast cells: an ambiguous relationship	3
Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review	3
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient	3
Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis	3

Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy	3
Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma	3
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials	3
BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome	3
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma	3
Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors	3
The impact of statins on melanoma survival: a systematic review and meta-analysis	3
Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients	3
Melanocytic neoplasms in neurofibromatosis type 1: a systematic review	3
Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma	3
Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma	3
Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice	3
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma	3
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma: Erratum	3
LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization	3
The number needed to biopsy for cutaneous melanoma in academic dermatology clinics	3
The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease	3
Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases	3
Melanoma risk during immunomodulating treatment	3
Nivolumab exposure in a hemodialysis patient with metastatic melanoma	3
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-li	3
Ultraviolet A radiation exposure and melanoma: a review	3
Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival	3
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II	3
Macrophage inhibitory cytokine-1 produced by melanoma cells contributes to melanoma tumor growth and metastasis in vivo by enhancing tumor vascularization	3
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	3